Immunomatics Receives $100,000 Investment From GenDx Cofounder

Oct 7, 2026
Myosotis Investments founder Wietse Mulder invested $100,000 in Immunomatics and joined the transplant technology company as a strategic adviser.

Immunomatics received a $100,000 investment from Myosotis Investments, the company announced in a press release. Myosotis founder and GenDx cofounder Wietse Mulder also joined Immunomatics as a strategic adviser.

Immunomatics is developing AI tools that combine transplant outcomes, HLA typing and machine learning to assess compatibility risks between donors and recipients. The company plans to use the technology to support donor selection for solid organ and blood stem cell transplants.

The company is expanding its clinical data, validating its models and preparing a regulatory strategy. It previously received a $207,740 NIH small business award and is collaborating with the UC San Diego Transplantation Lab.

We hope you enjoyed this article

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.